newsfilter
← Latest News
GlobeNewswire·

SRX Global Provides Update on Engineered T-Cell Strategy Following Pfizer–Starna Licensing Agreement

  • Pfizer announced a licensing agreement with Starna Therapeutics for three pre-IND in vivo CAR-T programs targeting autoimmune diseases, involving a $330 million upfront payment & potential up to $2.3 billion in milestones & royalties.
  • SRX Global Inc. commented on the Pfizer-Starna deal to highlight industry interest in engineered T-cell platforms while clarifying that SRX & CERo Therapeutics are not parties to the agreement.
  • SRX is proceeding with its pending definitive purchase agreement to acquire CERo Therapeutics, an operating subsidiary of CERo Therapeutics Holdings Inc.
  • CERo's lead candidate, CER-1236, utilizes a proprietary Chimeric Engulfment Receptor T cell (CER-T) platform designed to engage innate & adaptive immunity for hematologic malignancies.
  • The ongoing Phase 1/1b CERTAIN-T trial has dosed seven patients as of November 3, 2026, including the fourth patient in the second cohort.
  • CERo reported no dose-limiting toxicities, no cytokine release syndrome, & no neurotoxicity in previously treated patients, along with observed expansion of infused CER-1236 cells.
  • The CERTAIN-T trial has expanded its sites to include the University of California, Davis, which serves as the primary manufacturing facility for CER-1236.
  • The trial initially enrolled patients with acute myeloid leukemia but has been amended to include transfusion-dependent myelodysplastic syndromes, high-risk myelodysplastic syndromes, & post-JAK inhibitor myelofibrosis.
  • SRX CEO Kent Cunningham stated that the Pfizer deal does not serve as a valuation benchmark for CERo but reinforces the strategic importance of the engineered T-cell field.
Company
SRX Global Inc
Keywords
NYSE:SRXH, SRX Global Inc